Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer

被引:18
作者
Samar Masoumi Moghaddam
Afshin Amini
David L. Morris
Mohammad H. Pourgholami
机构
[1] University of New South Wales,Cancer Research Laboratories, Department of Surgery, St George Hospital
[2] University of New South Wales,Department of Surgery, St George Hospital
来源
Cancer and Metastasis Reviews | 2012年 / 31卷
关键词
Angiogenesis; Bevacizumab; Malignant ascites; Ovarian cancer; Peritoneal carcinomatosis; Vascular endothelial growth factor;
D O I
暂无
中图分类号
学科分类号
摘要
Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis which drives endothelial cell survival, proliferation, and migration while increasing vascular permeability. Playing an important role in the physiology of normal ovaries, VEGF has also been implicated in the pathogenesis of ovarian cancer. Essentially by promoting tumor angiogenesis and enhancing vascular permeability, VEGF contributes to the development of peritoneal carcinomatosis associated with malignant ascites formation, the characteristic feature of advanced ovarian cancer at diagnosis. In both experimental and clinical studies, VEGF levels have been inversely correlated with survival. Moreover, VEGF inhibition has been shown to inhibit tumor growth and ascites production and to suppress tumor invasion and metastasis. These findings have laid the basis for the clinical evaluation of agents targeting VEGF signaling pathway in patients with ovarian cancer. In this review, we will focus on VEGF involvement in the pathophysiology of ovarian cancer and its contribution to the disease progression and dissemination.
引用
收藏
页码:143 / 162
页数:19
相关论文
共 1205 条
[1]  
Geva E(2000)Role of vascular endothelial growth factor in ovarian physiology and pathology Fertility and Sterility 74 429-438
[2]  
Jaffe RB(2010)Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 International Journal of Cancer 127 2893-2917
[3]  
Ferlay J(2005)Angiogenesis in normal and neoplastic ovaries Angiogenesis 8 169-182
[4]  
Shin HR(1997)The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer International Journal of Gynecological Pathology 16 256-262
[5]  
Bray F(1996)Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity Cancer Science 87 963-971
[6]  
Forman D(1997)Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels British Journal of Cancer 76 1221-1227
[7]  
Mathers C(1997)Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas Cancer Letters 121 169-175
[8]  
Parkin DM(2003)Multidetector CT of peritoneal carcinomatosis from ovarian cancer1 RadioGraphics 23 687-701
[9]  
Ramakrishnan S(2011)Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study Cancer Chemotherapy and Pharmacology 68 267-274
[10]  
Subramanian IV(2010)Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer Transl Oncol 3 230-238